| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 39 | 2025 | 1038 | 10.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 43 | 2024 | 397 | 8.010 |
Why?
|
| Carcinoma, Hepatocellular | 24 | 2024 | 938 | 4.990 |
Why?
|
| Hepatitis C, Chronic | 19 | 2023 | 324 | 4.800 |
Why?
|
| Liver Neoplasms | 25 | 2024 | 1319 | 4.510 |
Why?
|
| Hepatitis C | 15 | 2023 | 364 | 4.430 |
Why?
|
| End Stage Liver Disease | 21 | 2024 | 182 | 4.040 |
Why?
|
| Liver Diseases, Alcoholic | 10 | 2023 | 57 | 3.570 |
Why?
|
| Antiviral Agents | 18 | 2023 | 746 | 2.800 |
Why?
|
| Liver Cirrhosis | 33 | 2024 | 833 | 2.700 |
Why?
|
| Hepacivirus | 13 | 2023 | 241 | 2.610 |
Why?
|
| Waiting Lists | 13 | 2024 | 228 | 2.230 |
Why?
|
| Fatty Liver | 10 | 2025 | 183 | 2.180 |
Why?
|
| Tissue and Organ Procurement | 6 | 2018 | 216 | 2.090 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 358 | 2.020 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 374 | 2.010 |
Why?
|
| Tissue Donors | 9 | 2024 | 486 | 2.000 |
Why?
|
| Nutrition Surveys | 23 | 2025 | 291 | 1.900 |
Why?
|
| Gastrointestinal Diseases | 3 | 2021 | 333 | 1.630 |
Why?
|
| United States | 60 | 2025 | 10767 | 1.580 |
Why?
|
| Betacoronavirus | 5 | 2020 | 286 | 1.480 |
Why?
|
| Humans | 141 | 2025 | 124327 | 1.320 |
Why?
|
| Hospitalization | 13 | 2024 | 1753 | 1.240 |
Why?
|
| Pandemics | 15 | 2024 | 1102 | 1.220 |
Why?
|
| Hepatitis, Alcoholic | 4 | 2021 | 26 | 1.210 |
Why?
|
| Risk Factors | 35 | 2025 | 10139 | 1.170 |
Why?
|
| Retrospective Studies | 44 | 2025 | 16223 | 1.140 |
Why?
|
| Organ Transplantation | 2 | 2020 | 164 | 1.120 |
Why?
|
| Graft Survival | 9 | 2025 | 528 | 1.120 |
Why?
|
| Hepatitis B, Chronic | 5 | 2023 | 82 | 1.100 |
Why?
|
| Adult | 56 | 2025 | 29378 | 1.090 |
Why?
|
| Prevalence | 22 | 2025 | 2428 | 1.030 |
Why?
|
| Middle Aged | 53 | 2025 | 26442 | 0.990 |
Why?
|
| Alcohol Drinking | 3 | 2023 | 339 | 0.940 |
Why?
|
| Liver | 11 | 2025 | 1761 | 0.940 |
Why?
|
| Elasticity Imaging Techniques | 6 | 2024 | 127 | 0.930 |
Why?
|
| Mortality | 4 | 2021 | 229 | 0.900 |
Why?
|
| Transplant Recipients | 3 | 2021 | 214 | 0.870 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2023 | 46 | 0.840 |
Why?
|
| Liver Failure | 3 | 2017 | 89 | 0.820 |
Why?
|
| Male | 64 | 2025 | 60989 | 0.810 |
Why?
|
| Cause of Death | 15 | 2025 | 468 | 0.810 |
Why?
|
| Proton Pump Inhibitors | 3 | 2020 | 261 | 0.810 |
Why?
|
| Healthcare Disparities | 3 | 2022 | 430 | 0.790 |
Why?
|
| Drug Overdose | 2 | 2020 | 65 | 0.760 |
Why?
|
| Coinfection | 2 | 2023 | 172 | 0.760 |
Why?
|
| Female | 63 | 2025 | 66265 | 0.750 |
Why?
|
| Aged | 31 | 2025 | 19460 | 0.750 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2020 | 75 | 0.740 |
Why?
|
| Alcohol-Related Disorders | 1 | 2019 | 34 | 0.660 |
Why?
|
| Length of Stay | 7 | 2021 | 1307 | 0.660 |
Why?
|
| Gastrectomy | 2 | 2017 | 90 | 0.650 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 215 | 0.650 |
Why?
|
| Liver Diseases | 5 | 2023 | 366 | 0.650 |
Why?
|
| Probiotics | 1 | 2021 | 208 | 0.620 |
Why?
|
| Hepatitis C Antibodies | 1 | 2018 | 21 | 0.620 |
Why?
|
| DNA, Viral | 2 | 2018 | 479 | 0.580 |
Why?
|
| Diabetes Mellitus | 6 | 2024 | 853 | 0.570 |
Why?
|
| Mesenteric Veins | 1 | 2017 | 15 | 0.560 |
Why?
|
| Shock, Hemorrhagic | 1 | 2017 | 51 | 0.550 |
Why?
|
| Portal Vein | 1 | 2017 | 92 | 0.540 |
Why?
|
| Severity of Illness Index | 11 | 2024 | 2896 | 0.540 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 223 | 0.540 |
Why?
|
| Hospital Mortality | 4 | 2020 | 1020 | 0.540 |
Why?
|
| Time Factors | 13 | 2024 | 6262 | 0.540 |
Why?
|
| Skilled Nursing Facilities | 1 | 2016 | 5 | 0.530 |
Why?
|
| Transplants | 1 | 2016 | 35 | 0.520 |
Why?
|
| Postoperative Complications | 3 | 2025 | 3062 | 0.520 |
Why?
|
| Secondary Prevention | 1 | 2017 | 214 | 0.510 |
Why?
|
| Cardiovascular Diseases | 7 | 2025 | 1886 | 0.500 |
Why?
|
| Health Care Costs | 4 | 2024 | 368 | 0.500 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 181 | 0.490 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2019 | 233 | 0.480 |
Why?
|
| Hospital Costs | 1 | 2016 | 178 | 0.470 |
Why?
|
| Databases, Factual | 8 | 2022 | 1174 | 0.460 |
Why?
|
| Hepatic Encephalopathy | 4 | 2023 | 75 | 0.450 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 692 | 0.450 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 247 | 0.440 |
Why?
|
| Risk Assessment | 13 | 2024 | 3371 | 0.420 |
Why?
|
| Cholangiocarcinoma | 3 | 2024 | 107 | 0.420 |
Why?
|
| Treatment Outcome | 17 | 2025 | 12279 | 0.420 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2023 | 44 | 0.410 |
Why?
|
| Proportional Hazards Models | 7 | 2025 | 1320 | 0.410 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2025 | 57 | 0.410 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2024 | 18 | 0.410 |
Why?
|
| Young Adult | 13 | 2025 | 8978 | 0.400 |
Why?
|
| Patient Readmission | 3 | 2020 | 377 | 0.390 |
Why?
|
| Laparoscopy | 1 | 2017 | 489 | 0.380 |
Why?
|
| HIV Infections | 2 | 2023 | 1888 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 1017 | 0.370 |
Why?
|
| Aged, 80 and over | 10 | 2024 | 6467 | 0.370 |
Why?
|
| Cross-Sectional Studies | 10 | 2024 | 3425 | 0.350 |
Why?
|
| Registries | 4 | 2019 | 1410 | 0.320 |
Why?
|
| Incidence | 6 | 2025 | 3086 | 0.310 |
Why?
|
| Hypothyroidism | 2 | 2020 | 93 | 0.300 |
Why?
|
| Health Status Disparities | 3 | 2020 | 227 | 0.300 |
Why?
|
| Inpatients | 4 | 2020 | 496 | 0.300 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 261 | 0.290 |
Why?
|
| Recurrence | 3 | 2021 | 1423 | 0.280 |
Why?
|
| Cohort Studies | 7 | 2024 | 4730 | 0.260 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 129 | 0.240 |
Why?
|
| Preoperative Period | 3 | 2020 | 87 | 0.240 |
Why?
|
| Cholangitis | 1 | 2025 | 35 | 0.240 |
Why?
|
| Troponin | 1 | 2025 | 72 | 0.240 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 63 | 0.230 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2025 | 723 | 0.230 |
Why?
|
| Organ Preservation | 1 | 2025 | 45 | 0.230 |
Why?
|
| Depression | 3 | 2023 | 1248 | 0.230 |
Why?
|
| Donor Selection | 1 | 2024 | 55 | 0.230 |
Why?
|
| Pulse Wave Analysis | 1 | 2024 | 45 | 0.230 |
Why?
|
| Telemedicine | 2 | 2023 | 434 | 0.230 |
Why?
|
| Hepatitis A | 1 | 2024 | 32 | 0.220 |
Why?
|
| Republic of Korea | 1 | 2024 | 38 | 0.220 |
Why?
|
| Perfusion | 1 | 2025 | 203 | 0.220 |
Why?
|
| Age Distribution | 3 | 2019 | 413 | 0.220 |
Why?
|
| Opiate Substitution Treatment | 2 | 2021 | 25 | 0.220 |
Why?
|
| Adolescent | 6 | 2024 | 19354 | 0.210 |
Why?
|
| Vascular Stiffness | 1 | 2024 | 72 | 0.210 |
Why?
|
| Policy | 1 | 2023 | 34 | 0.210 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 998 | 0.200 |
Why?
|
| California | 2 | 2020 | 128 | 0.200 |
Why?
|
| Cost of Illness | 2 | 2021 | 246 | 0.200 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2023 | 64 | 0.200 |
Why?
|
| Bile Duct Neoplasms | 1 | 2023 | 110 | 0.190 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 582 | 0.190 |
Why?
|
| Integrases | 1 | 2023 | 161 | 0.190 |
Why?
|
| HIV | 1 | 2023 | 180 | 0.190 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 24 | 0.190 |
Why?
|
| Hepatitis B | 1 | 2023 | 160 | 0.190 |
Why?
|
| Prebiotics | 1 | 2021 | 23 | 0.190 |
Why?
|
| Alcohol Abstinence | 1 | 2021 | 14 | 0.190 |
Why?
|
| Cholestasis | 1 | 2023 | 154 | 0.190 |
Why?
|
| Viremia | 1 | 2022 | 128 | 0.190 |
Why?
|
| Health Care Rationing | 1 | 2021 | 58 | 0.180 |
Why?
|
| Gallbladder Neoplasms | 1 | 2021 | 14 | 0.180 |
Why?
|
| Military Personnel | 1 | 2023 | 211 | 0.180 |
Why?
|
| Tacrolimus | 1 | 2021 | 99 | 0.180 |
Why?
|
| Hypernatremia | 1 | 2021 | 29 | 0.180 |
Why?
|
| Age Factors | 4 | 2024 | 2805 | 0.180 |
Why?
|
| Hyponatremia | 1 | 2021 | 72 | 0.180 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 31 | 0.180 |
Why?
|
| Sarcopenia | 1 | 2021 | 39 | 0.180 |
Why?
|
| Exercise | 3 | 2021 | 820 | 0.170 |
Why?
|
| Hepatitis B virus | 2 | 2023 | 136 | 0.170 |
Why?
|
| Dysbiosis | 1 | 2021 | 122 | 0.170 |
Why?
|
| Biliary Atresia | 1 | 2023 | 190 | 0.170 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 317 | 0.170 |
Why?
|
| Prediabetic State | 1 | 2021 | 57 | 0.170 |
Why?
|
| Peritonitis | 2 | 2017 | 75 | 0.170 |
Why?
|
| Digestive System Diseases | 1 | 2020 | 17 | 0.170 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2020 | 80 | 0.170 |
Why?
|
| Drug Monitoring | 1 | 2021 | 168 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1127 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1417 | 0.170 |
Why?
|
| Thyroid Gland | 1 | 2020 | 113 | 0.170 |
Why?
|
| Causality | 1 | 2019 | 83 | 0.170 |
Why?
|
| Methadone | 1 | 2020 | 124 | 0.160 |
Why?
|
| Analgesics, Opioid | 2 | 2021 | 408 | 0.160 |
Why?
|
| Entamoebiasis | 1 | 2019 | 3 | 0.160 |
Why?
|
| Fibrosis | 4 | 2024 | 432 | 0.160 |
Why?
|
| Entamoeba histolytica | 1 | 2019 | 17 | 0.160 |
Why?
|
| Phenols | 1 | 2019 | 55 | 0.160 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 32 | 0.160 |
Why?
|
| Colonic Diseases | 1 | 2019 | 38 | 0.150 |
Why?
|
| Disease Progression | 6 | 2022 | 2038 | 0.150 |
Why?
|
| Benzhydryl Compounds | 1 | 2019 | 65 | 0.150 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 243 | 0.150 |
Why?
|
| Health Policy | 1 | 2020 | 212 | 0.150 |
Why?
|
| Marijuana Abuse | 1 | 2019 | 49 | 0.150 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 330 | 0.150 |
Why?
|
| Sex Distribution | 1 | 2019 | 297 | 0.150 |
Why?
|
| Global Burden of Disease | 1 | 2017 | 25 | 0.150 |
Why?
|
| Bacterial Infections | 2 | 2017 | 306 | 0.140 |
Why?
|
| Rifamycins | 1 | 2017 | 21 | 0.140 |
Why?
|
| Licensed Practical Nurses | 1 | 2017 | 1 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 645 | 0.140 |
Why?
|
| Sofosbuvir | 1 | 2017 | 14 | 0.140 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 25 | 0.140 |
Why?
|
| Hepatorenal Syndrome | 1 | 2017 | 28 | 0.140 |
Why?
|
| Nutritional Support | 1 | 2017 | 54 | 0.140 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 314 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 187 | 0.140 |
Why?
|
| Carbamates | 1 | 2017 | 60 | 0.140 |
Why?
|
| Thrombophilia | 1 | 2017 | 43 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 685 | 0.140 |
Why?
|
| United States Health Resources and Services Administration | 1 | 2016 | 3 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 260 | 0.130 |
Why?
|
| Medically Underserved Area | 1 | 2017 | 90 | 0.130 |
Why?
|
| Clostridium Infections | 1 | 2020 | 245 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 5106 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3268 | 0.130 |
Why?
|
| Income | 1 | 2016 | 133 | 0.130 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 201 | 0.130 |
Why?
|
| Heparin | 1 | 2017 | 228 | 0.120 |
Why?
|
| Educational Status | 1 | 2016 | 272 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1149 | 0.120 |
Why?
|
| Nutritional Status | 1 | 2017 | 312 | 0.120 |
Why?
|
| Survival Analysis | 4 | 2022 | 1482 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2824 | 0.120 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 157 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2016 | 137 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 286 | 0.120 |
Why?
|
| Health Resources | 1 | 2016 | 115 | 0.120 |
Why?
|
| Heterozygote | 1 | 2017 | 676 | 0.120 |
Why?
|
| Malnutrition | 1 | 2017 | 203 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 719 | 0.120 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 240 | 0.120 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 605 | 0.110 |
Why?
|
| Survival Rate | 4 | 2020 | 2020 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2016 | 376 | 0.110 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 634 | 0.110 |
Why?
|
| Allografts | 2 | 2025 | 190 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2017 | 586 | 0.100 |
Why?
|
| Kidney | 1 | 2019 | 1345 | 0.100 |
Why?
|
| Veterans | 1 | 2023 | 1751 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 449 | 0.100 |
Why?
|
| Decision Making | 1 | 2016 | 656 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 874 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2023 | 6084 | 0.090 |
Why?
|
| Comorbidity | 3 | 2023 | 1514 | 0.090 |
Why?
|
| Morbidity | 2 | 2023 | 244 | 0.090 |
Why?
|
| Prognosis | 4 | 2023 | 4554 | 0.090 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2023 | 52 | 0.090 |
Why?
|
| Medicaid | 2 | 2023 | 243 | 0.090 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 87 | 0.090 |
Why?
|
| ROC Curve | 2 | 2023 | 562 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 540 | 0.080 |
Why?
|
| Ascites | 2 | 2023 | 88 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2018 | 1182 | 0.080 |
Why?
|
| Censuses | 2 | 2019 | 11 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2087 | 0.080 |
Why?
|
| Child | 3 | 2024 | 24516 | 0.080 |
Why?
|
| Sex Factors | 2 | 2024 | 1267 | 0.080 |
Why?
|
| Biopsy | 2 | 2023 | 1237 | 0.070 |
Why?
|
| Quality of Life | 1 | 2017 | 1949 | 0.070 |
Why?
|
| Linear Models | 2 | 2020 | 671 | 0.070 |
Why?
|
| SEER Program | 2 | 2021 | 199 | 0.070 |
Why?
|
| Ultrasonography | 2 | 2024 | 928 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2024 | 1550 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2021 | 1246 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 2416 | 0.060 |
Why?
|
| Logistic Models | 2 | 2020 | 1804 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 511 | 0.060 |
Why?
|
| Primary Graft Dysfunction | 1 | 2025 | 24 | 0.060 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 25 | 0.060 |
Why?
|
| Neoplasms | 1 | 2019 | 2794 | 0.060 |
Why?
|
| Reperfusion Injury | 1 | 2025 | 103 | 0.060 |
Why?
|
| Agent Orange | 1 | 2023 | 3 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1154 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2023 | 722 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 2122 | 0.050 |
Why?
|
| Mutation | 1 | 2017 | 5807 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2023 | 87 | 0.050 |
Why?
|
| Food Supply | 1 | 2024 | 100 | 0.050 |
Why?
|
| Living Donors | 1 | 2023 | 109 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2023 | 95 | 0.050 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2023 | 64 | 0.050 |
Why?
|
| Hand Strength | 1 | 2022 | 41 | 0.050 |
Why?
|
| Ethanol | 1 | 2023 | 163 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2022 | 75 | 0.050 |
Why?
|
| Acute Disease | 1 | 2025 | 1101 | 0.050 |
Why?
|
| Ontario | 1 | 2021 | 65 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2022 | 180 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2025 | 588 | 0.050 |
Why?
|
| Estradiol | 1 | 2023 | 534 | 0.050 |
Why?
|
| alpha-Fetoproteins | 1 | 2022 | 132 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 437 | 0.040 |
Why?
|
| Respiratory Protective Devices | 1 | 2020 | 9 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2021 | 121 | 0.040 |
Why?
|
| Animals | 1 | 2021 | 34134 | 0.040 |
Why?
|
| Obesity | 2 | 2024 | 2250 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 294 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 79 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 1099 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 136 | 0.040 |
Why?
|
| Death Certificates | 1 | 2019 | 9 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 152 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2023 | 668 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 84 | 0.040 |
Why?
|
| Paromomycin | 1 | 2019 | 3 | 0.040 |
Why?
|
| Weight Loss | 1 | 2023 | 482 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2018 | 60 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 88 | 0.040 |
Why?
|
| Antiprotozoal Agents | 1 | 2019 | 37 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 356 | 0.040 |
Why?
|
| Testosterone | 1 | 2023 | 534 | 0.040 |
Why?
|
| Myositis | 1 | 2019 | 54 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 749 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2018 | 41 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2020 | 473 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2020 | 376 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2016 | 13 | 0.030 |
Why?
|
| Patient Portals | 1 | 2017 | 20 | 0.030 |
Why?
|
| Computer Security | 1 | 2017 | 26 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 84 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2019 | 240 | 0.030 |
Why?
|
| Advanced Practice Nursing | 1 | 2016 | 9 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 136 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 223 | 0.030 |
Why?
|
| Safety-net Providers | 1 | 2017 | 52 | 0.030 |
Why?
|
| Confidentiality | 1 | 2017 | 99 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 2016 | 120 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2017 | 266 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2018 | 221 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 628 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 267 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 484 | 0.030 |
Why?
|
| Biomarkers | 1 | 2025 | 2977 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2018 | 295 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 540 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 349 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1333 | 0.030 |
Why?
|
| Palliative Care | 1 | 2019 | 432 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 505 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 677 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 418 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 402 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 951 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1241 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 688 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 1392 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1460 | 0.030 |
Why?
|
| Anxiety | 1 | 2020 | 966 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1612 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2016 | 387 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1264 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1887 | 0.030 |
Why?
|
| Communication | 1 | 2017 | 516 | 0.030 |
Why?
|
| Diet | 1 | 2020 | 1132 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2019 | 849 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8184 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 12476 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2020 | 14076 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 7167 | 0.010 |
Why?
|